Skip to main content
. 2020 Dec 10;45:101142. doi: 10.1016/j.molmet.2020.101142

Figure 5.

Figure 5

Glycemic control in the female WT and ERαadipoKO mice treated with EPO. (A–B) Body weight (A) and fat mass (B) of the WT and ERαadipoKO females on the NCD for 10 weeks. Symbols indicate the WT (filled circle, solid line) and ERα−/− (open square, dotted line) mice (n = 12/group). (C–D) Measurement of body weight (C) and fat mass (D) in the WT and ERαadipoKO females at 4 months with EPO or PBS treatment for 3 weeks on the HFD. Symbols indicate the WT PBS (filled circle, solid line) and EPO (open square, thin line)-treated mice and ERα−/− PBS (filled triangle, solid line) and EPO (open inverted triangle, dotted line)-treated mice. (n = 6–9/group, ∗ means PBS vs EPO in the ERα−/− mice, ∗p < 0.05, and ∗∗p < 0.01). (E–F) Body weight (E) and fat mass (F) of the WT and ERαadipoKO females on the HFD for 10 weeks. Symbols indicate the WT (filled circle, solid line) and ERα−/− (open square, dotted line) mice (n = 12/group). (G–H) Measurement of body weight (G) and fat mass (H) in the WT and ERαadipoKO females at 4 months on the HFD for 12 weeks. All mice were treated with EPO or PBS for the last 2 weeks (n = 6). Symbols indicate the WT PBS (filled circle, solid line) and EPO (open square, thin line)-treated mice and ERα−/− PBS (filled triangle, solid line) and EPO (open inverted triangle, dotted line)-treated mice. (I–L) The WT and ERαadipoKO females at 4 months on the HFD for 12 weeks with EPO or PBS treatment for the last 2 weeks were used. GTT (I) and ITT (J) were performed (n = 6–9/group, ∗, †, ‡, §p < 0.05, ∗∗, ††, ‡‡, §§p < 0.01, ∗ means PBS vs EPO in the ERα−/− mice, † means PBS vs EPO in the WT mice, ‡ means EPO in ERα−/− vs EPO in WT, § means PBS in the ERα−/− vs PBS in WT). Fasting glucose levels (K) and expression of insulin receptor gene (L) were measured.